AbbVie Inc.

AbbVie Inc.

ABBV

$288.94

Updated: 03/11/2026, 07:13:10

Market Cap
$510.59B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US

No historical data available

Company Profile

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

USD
NYSE
CEO: Robert A. Michael
Employees: 57,000
https://www.abbvie.com
Asset Summaries
Latest generated summaries for ABBV

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
ABBV-10-k-fy2025.html3.6 MBtext/htmlENFiled 20/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 65 KPI observations

Revenue

$61.2B

FY 2025 · Reported

Net income

$4.2B

FY 2025 · Reported

Gross margin

70.2%

FY 2025 · Calculated

Free cash flow

$17.8B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$1.0B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Elahere — first-in-class ADC
Rinvoq regulatory and clinical milestones
Qulipta pipeline developments

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Global biopharmaceutical company; single global business segment with leadership in immunology, neuroscience, oncology and aesthetics

98%
Source evidence
“AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics.”

Principal business and geographic distribution model

In the US AbbVie distributes pharmaceutical products principally through independent wholesale distributors; outside the US it sells primarily to wholesalers/distributors and works through national payer systems.

95%
Source evidence
“In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, patients or other customers.”

Distribution channels worldwide

Products sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers; aesthetic products and devices also sold directly to physicians.

95%
Source evidence
“AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses.”

Distribution channels

Products sold worldwide to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers; aesthetic products also sold directly to physicians

95%
Source evidence
“AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers”

Elahere — first-in-class ADC

Elahere: first-in-class ADC approved for platinum-resistant ovarian cancer (via ImmunoGen)

97%
Source evidence
“its flagship cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer”

Rinvoq regulatory and clinical milestones

Rinvoq: GCA approvals (US/EU), positive AA and vitiligo Phase 3 data, RA head-to-head superiority vs Humira, updated IBD indication

93%
Source evidence
“In October 2025, AbbVie announced that the U.S. FDA approved a supplemental New Drug Application (sNDA) that updates the indication statement for Rinvoq”

Qulipta pipeline developments

Qulipta: Phase 3 menstrual migraine trial initiated; positive TEMPLE head-to-head vs topiramate; ECLIPSE acute migraine study met endpoints

90%
Source evidence
“In December 2025, AbbVie announced results from the Phase 3 ECLIPSE study, evaluating the safety, efficacy and tolerability of Aquipta versus placebo for the acute treatment of migraine in adults.”

Positioning and strategy

ImmunoGen acquisition (Feb 2024)

ImmunoGen acquired 2/12/2024 for $31.26/share cash; $9.8B total ($9.2B net of cash); Elahere ADC; goodwill $1,249M

99%
Source evidence
“AbbVie acquired all outstanding shares of ImmunoGen for $31.26 per share in cash. The total fair value of the consideration transferred to owners of ImmunoGen common stock was $9.8 billion ($9.2 billion, net of cash acquired).”

Gilgamesh Pharmaceuticals acquisition (Oct 2025)

Gilgamesh acquired Oct 2025 for $906M upfront (asset acquisition); ABBV-2505 for MDD; up to $300M milestones

98%
Source evidence
“AbbVie made an upfront cash payment of $906 million to acquire all outstanding equity of Gilgamesh and the transaction was accounted for as an asset acquisition”

Cerevel Therapeutics acquisition financing liability and losses

Cerevel: $246M financing liability; Pfizer license milestones up to $1.6B; 2024 operating losses $4.9B incl. $4.5B emraclidine impairment

98%
Source evidence
“For the period from the acquisition date through December 31, 2024, operating losses attributable to Cerevel Therapeutics were $4.9 billion, inclusive of an intangible asset impairment charge of $4.5 billion related to emraclidine.”

RemeGen RC148 license (announced after Dec 31, 2025)

RemeGen: $650M upfront, up to $5.0B milestones, RC148 PD-1/VEGF bispecific, global ex-China; close expected 2026

97%
Source evidence
“AbbVie will make an upfront payment of $650 million and receive an exclusive global license excluding China to develop, manufacture and commercialize RC148”

Ichnos Glenmark Innovation license (Sep 2025)

IGI license: ISB-2001/ABBV-2001 for multiple myeloma; $700M upfront; up to $1.2B milestones

97%
Source evidence
“The upfront payment of $700 million was recorded in acquired IPR&D and milestones expense in the consolidated statement of earnings in the third quarter of 2025.”

Capstan Therapeutics acquisition (Aug 2025)

Capstan acquired Aug 2025: ABBV-619 tLNP anti-CD19 CAR-T for autoimmune diseases

95%
Source evidence
“a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate in development for the treatment of B cell-mediated autoimmune diseases”

U.S. capital investment projects

U.S. capex: new API facility in Illinois, biologics manufacturing/R&D expansion in Massachusetts, agreement to acquire Arizona device manufacturing facility

94%
Source evidence
“In 2025, AbbVie announced the start of construction of a new active pharmaceutical ingredient facility in Illinois and an expansion of biologics manufacturing and research and development capacity in Massachusetts.”

Key on-market growth products

Key on-market growth products: Skyrizi, Rinvoq, Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev, Venclexta, Elahere, Botox Cosmetic, Juvederm Collection

96%
Source evidence
“Maximizing revenue growth of our key on-market products, including Skyrizi, Rinvoq, Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev, Venclexta, Elahere, Botox Cosmetic and Juvederm Collection.”

Pipeline scale and focus

Pipeline of ~90 compounds/devices/indications, ~60 in mid- and late-stage; focused on immunology, neuroscience, oncology, aesthetics and obesity

96%
Source evidence
“AbbVie's pipeline currently includes approximately 90 compounds, devices or indications in development individually or under collaboration or license agreements. Of these programs, approximately 60 are in mid- and late-stage development.”

2026 strategic objectives

2026 objectives: diversified growth drivers, commercial execution, pipeline expansion (incl. obesity), strong dividend and investment grade credit rating

95%
Source evidence
“generating substantial operating cash flows to support investments in innovative research and development and returning cash to shareholders via a strong and growing dividend while maintaining a strong investment grade credit rating”

Strategic rationale of oncology/neuroscience acquisitions

Acquisitions accelerate entry into solid tumors (ADC) and expand neuroscience pipeline

94%
Source evidence
“The combination accelerated AbbVie's entry into the solid tumor space and strengthened its oncology pipeline.”

Risks, financing, and outlook

Notable 2025 costs

2025 costs: $7.4B intangible amortization; $6.5B change in fair value of contingent consideration; $847M intangible impairment; $276M acquisition/integration expenses

97%
Source evidence
“(i) $7.4 billion related to the amortization of intangible assets; (ii) $6.5 billion for the change in fair value of contingent consideration liabilities; (iii) $847 million related to intangible asset impairment; and (iv) $276 million of acquisition and integration expenses.”

Debt obligations could require cash flow for interest and refinancing risk

AbbVie has incurred and intends to incur significant debt; cash flow from operations may not be sufficient to repay all outstanding debt as it becomes due.

93%
Source evidence
“AbbVie's cash flow from operations may not be sufficient to repay all of the outstanding debt as it becomes due, and AbbVie may not be able to borrow money, sell assets, or otherwise raise funds on acceptable terms, or at all, to refinance its debt.”

Near-term regulatory activity

Expects several regulatory submissions, approvals and data readouts and multiple mid-stage-to-late-stage program transitions in the next 12 months

90%
Source evidence
“AbbVie anticipates several regulatory submissions, approvals and data readouts from key clinical trials in the next 12 months.”

ImmunoGen post-acquisition results 2024

ImmunoGen 2024 post-acquisition: revenues $578M; operating losses $682M

97%
Source evidence
“net revenues attributable to ImmunoGen were $578 million and operating losses attributable to ImmunoGen were $682 million”

Unaudited pro forma combined results (AbbVie + ImmunoGen + Cerevel)

Pro forma combined (as if acquired 1/1/2023): net revenues $56,389M (2024) / $54,691M (2023); net earnings $4,564M / $2,862M

97%
Source evidence
“Net revenues$56,389 $54,691 Net earnings4,564 2,862”

ImmunoGen acquired intangible assets detail

ImmunoGen intangibles: $7,200M developed product rights, $125M licenses, $1,280M IPR&D; goodwill $1,249M (non-deductible)

96%
Source evidence
“Intangible assets relate to $7.3 billion of definite-lived intangible assets and $1.3 billion of acquired IPR&D associated with products that have not yet received regulatory approval.”

Cerevel acquisition-related expenses 2024

Acquisition-related expenses (regulatory, advisory, legal fees): Cerevel $44M; ImmunoGen $59M (2024, in SG&A)

95%
Source evidence
“Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $59 million for the year ended December 31, 2024”

Voluntary agreement with U.S. government

Post-year-end voluntary agreement with U.S. government: Medicaid low prices, $100B U.S. R&D/capex pledge over a decade, three-year tariff/price-mandate exemption

93%
Source evidence
“AbbVie pledged $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade. Under this voluntary agreement, the U.S. government has agreed to provide AbbVie a three-year exemption from tariffs and future price mandates.”

IRA Medicare drug price setting: Imbruvica (2026), Vraylar and Linzess (2027), Botox (2028)

Under the IRA, HHS can effectively set Medicare prices; government prices can apply as soon as nine years (small-molecule) or 13 years (biologics) from FDA approval

98%
Source evidence
“In January 2026, Botox was selected as one of 15 medicines subject to government-set prices in Medicare Parts B and D beginning January 1, 2028.”

IRA Medicare price-setting

IRA government-set Medicare prices: Imbruvica (2026), Vraylar and Linzess (2027), Botox (Parts B & D, 2028); more products could be selected

97%
Source evidence
“In January 2026, Botox was selected as one of 15 medicines subject to government-set prices in Medicare Parts B and D beginning in 2028.”

IRA Part D redesign: 10% manufacturer discount replaces 70% coverage gap discount beginning January 2025

Beginning January 2025, the IRA replaced the 70% coverage gap discount with a 10% manufacturer discount for Part D beneficiaries past deductible

95%
Source evidence
“beginning in January 2025, under the IRA, the 70% coverage gap discount program was replaced by a 10% manufacturer discount for all Medicare Part D beneficiaries that have met their deductibl”

Multi-jurisdiction drug approval requirements

Country-specific clinical data requirements in Japan, China, South Korea, Taiwan, India and Russia; EMA centralized procedure in the EU

94%
Source evidence
“Clinical data in Chinese subjects are usually required to support approval in China, requiring the inclusion of China in global pivotal studies, or a separate China/Asian clinical trial.”

Post-approval cGMP and FDA inspection obligations

FDA periodically inspects manufacturing facilities for cGMP compliance; certain manufacturing changes require prior FDA approval

93%
Source evidence
“The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural and record keeping requirements.”

International operations risks including FCPA and UK Bribery Act

International operations expose AbbVie to labor regulations, tax law changes, instability, expropriation, and anti-corruption laws including FCPA and UK Bribery Act.

90%
Source evidence
“potential penalties or other adverse consequences for violations of anti-corruption, anti-bribery and other similar laws and regulations, including the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act”

Intangible asset and goodwill impairment risk

Developed product rights and other intangibles of $52.6 billion and goodwill of $35.6 billion subject to impairment testing; IPR&D assets carry significant failure risk.

97%
Source evidence
“As of December 31, 2025, the carrying value of AbbVie’s developed product rights and other intangible assets was $52.6 billion and the carrying value of AbbVie’s goodwill was $35.6 billion.”

Pricing pressure and cost-containment efforts

Downward pressure on product pricing in the US, EU member states and other countries; increasing public and legislative pressure on pharmaceutical pricing

96%
Source evidence
“In the United States, European Union member states and other countries, AbbVie's business has experienced downward pressure on product pricing, and this pressure could increase in the future.”

IT systems, cybersecurity and AI adoption risk

Failure of, or disruption to, IT systems or inadequate adoption of emerging technologies such as AI could have a material adverse effect on AbbVie's business.

95%
Source evidence
“AbbVie utilizes AI and other emerging technologies in select applications to support its operations. These technologies may present opportunities for AbbVie's business but may also entail risks, including that AI-generated analyses utilized by AbbVie could be deficient or exacerbate regulatory, cybersecurity or other significant risks.”

R&D pipeline failure risk

Failure to launch successful new products or new indications may cause AbbVie's products to become obsolete

95%
Source evidence
“A high rate of failure in the biopharmaceutical industry is inherent in the research and development of new products, and failure can occur at any point in the research and development process”

Third-party IP infringement claims

A successful claim of patent or other intellectual property infringement could subject AbbVie to significant damages or an injunction

93%
Source evidence
“A successful claim of patent or other intellectual property infringement could subject AbbVie to significant damages or an injunction preventing the manufacture, sale, or use of the affected AbbVie product”

Compulsory licensing and IP challenges by governments

Compulsory licenses may diminish or eliminate sales and profits from those jurisdictions; America Invents Act created inter partes review and post grant review procedures

92%
Source evidence
“certain governments outside the United States have indicated that compulsory licenses to patents may be sought to further their domestic policies or on the basis of national emergencies, such as HIV/AIDS.”

Patent litigation cost and unpredictability

Manufacturers of generics file ANDAs seeking to market generic forms prior to patent expiration, asserting patents are invalid, unenforceable and/or not infringed

92%
Source evidence
“manufacturers of generic pharmaceutical products file, and may continue to file, Abbreviated New Drug Applications with the FDA seeking to market generic forms of AbbVie's products prior to the expiration of relevant patents”

Credit rating downgrade risk

Loss of investment grade credit rating or unavailable funds on acceptable terms could hinder expansion and product development; debt covenants could restrict operations.

92%
Source evidence
“If AbbVie raises additional funds by issuing debt or entering into credit facilities, it may be subject to limitations on its operations due to restrictive covenants.”

Off-label promotion prohibition and labeling regulation

The FDA continues to regulate product labeling and prohibits the promotion of products for unapproved or 'off-label' uses

92%
Source evidence
“the FDA continues to regulate product labeling and prohibits the promotion of products for unapproved or "off-label" uses along with other labeling restrictions.”

Acquisitions and licensing may negatively affect profitability

Acquisitions, technology licensing, alliances and dispositions may incur significant expenses and negatively affect profitability.

90%
Source evidence
“These effects could cause a deterioration of AbbVie's credit rating and result in increased borrowing costs and interest expense.”

Dependence on attracting and retaining qualified personnel

Competition for qualified biopharmaceutical personnel is intense and increasing; failure to retain could affect development and commercialization.

90%
Source evidence
“Competition for qualified personnel in the biopharmaceutical field is intense and increasing.”

Commercialization execution risk

Failure to create market demand, ensure compliant manufacturing and efficient supply chain delivery could adversely affect revenues and financial condition.

90%
Source evidence
“ensuring that the active pharmaceutical ingredient(s) for a product and the finished product are manufactured in sufficient quantities and in compliance with requirements of the FDA and similar foreign regulatory agencies”

Counterfeit or diverted product risk

Illegal distribution and sale of counterfeit or unregistered versions of AbbVie products could materially harm reputation, business and results of operations.

90%
Source evidence
“The prevalence of counterfeit/diverted medicines is an industry-wide issue due to a variety of factors, including the adoption of e-commerce”

Material exposure graph

Skyrizi and Rinvoq
Revenue Exposure

Two products account for ~42% of 2025 net revenues, creating significant product concentration risk especially as patents expire.

Relevance 95·Dependency 92·Confidence 99
Source evidence
“in aggregate, these products accounted for approximately 42% of total net revenues in 2025.”
Wholesale distributors (US)
Revenue Exposure

US pharmaceutical revenue is principally generated through independent wholesale distributors per business description.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors”
Wholesale distributors (McKesson, Cardinal Health, Cencora)
Customer Exposure

Substantially all US pharmaceutical sales flow through three wholesalers; their financial difficulties could reduce orders and impair receivable collection.

Relevance 95·Dependency 90·Confidence 98
Source evidence
“If one of its significant wholesale distributors encounters financial or other difficulties, such distributor may decrease the amount of business that it does with AbbVie, and AbbVie may be unable to collect all the amounts that the distributor owes it”
Inflation Reduction Act (IRA)
Regulatory Exposure

IRA government-set Medicare prices for Imbruvica (2026), Vraylar and Linzess (2027), Botox (2028) plus the 10% Part D manufacturer discount may accelerate revenue erosion before IP expiration.

Relevance 92·Dependency 85·Confidence 97
Source evidence
“the IRA will have the effect of reducing prices and reimbursements for certain of our products, which could significantly impact AbbVie's results of operations.”
Inflation Reduction Act of 2022
Regulatory Exposure

IRA Medicare price-setting already covers Imbruvica, Vraylar, Linzess and Botox, and could accelerate revenue erosion on additional high-revenue products.

Relevance 92·Dependency 70·Confidence 95
Source evidence
“It is possible that more of our products, including products that generate substantial revenues, could be selected in future years, which could, among other things, accelerate revenue erosion prior to expiration of intellectual property protections.”
FDA and similar foreign regulatory agencies
Regulatory Exposure

Successful commercialization requires API and finished product manufacturing compliant with FDA and similar foreign regulatory agency requirements.

Relevance 90·Dependency 85·Confidence 90
Source evidence
“manufactured in sufficient quantities and in compliance with requirements of the FDA and similar foreign regulatory agencies and with acceptable quality and pricing to meet commercial demand”
United States
Regulatory Exposure

Voluntary agreement with U.S. government includes Medicaid pricing concessions and $100B U.S. investment pledge in exchange for a three-year tariff/price-mandate exemption.

Relevance 90·Dependency 65·Confidence 90
Source evidence
“AbbVie will provide low prices in Medicaid and expand affordable, direct-to-patient offerings. Additionally, AbbVie pledged $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade.”
Rinvoq
Demand Driver

Rinvoq is a named key on-market growth product with 2025 label expansions (GCA, IBD) and late-stage pipeline data supporting future growth; IP settled to April 2037.

Relevance 90·Dependency 60·Confidence 93
Source evidence
“Maximizing revenue growth of our key on-market products, including Skyrizi, Rinvoq, Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev, Venclexta, Elahere, Botox Cosmetic and Juvederm Collection.”
U.S. Food and Drug Administration
Regulatory Exposure

FDA post-approval obligations include cGMP compliance, facility inspections, prior approval of manufacturing changes, and possible post-marketing requirements.

Relevance 85·Dependency 80·Confidence 94
Source evidence
“quality control and manufacturing procedures must continue to conform to cGMP after approval, and certain changes to the manufacturing procedures and finished product must be submitted and approved by the FDA prior to implementation.”
Antibody-drug conjugates (ADC)
Technology Dependency

ImmunoGen acquisition brought ADC technology and pipeline, accelerating AbbVie's entry into solid tumors.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“ImmunoGen is a commercial-stage biotechnology company focused on the discovery, development and commercialization of antibody-drug conjugates (ADC) for cancer patients.”
Wholesale distributors
Customer Exposure

U.S. pharmaceutical products distributed principally through independent wholesale distributors; ex-U.S. sales primarily to wholesalers or through distributors.

Relevance 80·Dependency 75·Confidence 92
Source evidence
“In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors”
Government and payer cost containment
Cost Driver

Managed care practices, Medicare/Medicaid rules, and government cost containment create downward pricing pressure on revenues and operating earnings.

Relevance 80·Dependency 70·Confidence 94
Source evidence
“To the extent these cost containment efforts are not offset by greater demand, increased patient access to health care, or other factors, AbbVie's revenues and operating earnings will be reduced.”
Interest rates / debt service
Cost Driver

Rising interest rates or additional indebtedness would increase interest payments and reduce cash flow available for capex and growth.

Relevance 70·Dependency 60·Confidence 90
Source evidence
“To the extent AbbVie incurs additional indebtedness or interest rates increase, these risks could increase further.”
USD
Currency Exposure

Company reports constant currency growth alongside reported growth, indicating meaningful non-USD revenue exposure from worldwide operations.

Relevance 70·Dependency 55·Confidence 85
Source evidence
“Worldwide net revenues increased by 9% on a reported and on a constant currency basis.”
Artificial intelligence and emerging technologies
Technology Dependency

AbbVie uses AI in select operations; deficient AI analyses or failure to implement effectively could hinder competitiveness versus AI-advantaged competitors.

Relevance 65·Dependency 45·Confidence 90
Source evidence
“our failure to effectively implement these technologies could hinder our ability to compete, as competitors' advancements in AI may lead to more efficient operations”
Aesthetic products and devices
Revenue Exposure

Aesthetic products and devices are distinguished by being sold directly to physicians and licensed healthcare providers in addition to standard channels.

Relevance 60·Dependency 50·Confidence 90
Source evidence
“Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers.”
US Foreign Corrupt Practices Act / UK Bribery Act
Legal Exposure

International operations expose AbbVie to penalties for anti-corruption and anti-bribery law violations.

Relevance 60·Dependency 40·Confidence 90
Source evidence
“potential penalties or other adverse consequences for violations of anti-corruption, anti-bribery and other similar laws and regulations, including the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act”
Competition for qualified biopharmaceutical personnel
Competitive Exposure

Intense and increasing competition for qualified scientific, technical and management personnel creates retention and cost risk.

Relevance 55·Dependency 50·Confidence 90
Source evidence
“AbbVie cannot be sure that it will be able to attract and retain quality personnel or that the costs of doing so will not materially increase.”
Humira
Competitive Exposure

Rinvoq demonstrated superiority versus Humira in the SELECT-SWITCH head-to-head RA study, positioning Rinvoq competitively against the legacy franchise.

Relevance 55·Dependency 30·Confidence 85
Source evidence
“In the study, Rinvoq demonstrated superiority versus Humira in achieving low disease activity and remission.”
Full company information
Latest profile, trading, valuation, and identifier data stored for ABBV.
Share price
$288.94
Market cap
$510.59B
Exchange
NYSE
Currency
USD
CEO
Robert A. Michael
Employees
57,000
IPO date
02/01/2013
Beta
0.281
Last dividend
$0.00
Day range
$286.14 – $294.86
52-week range
$190.75 – $298.74
1-day performance
-2.02%
1-year performance
51.48%
Current drawdown (1Y)
-3.28%
CIK
0001551152
CUSIP
00287Y109
ISIN
US00287Y1091
Created
07/12/2025, 01:53:09
Last update
03/11/2026, 07:13:10

Track AbbVie Inc. with an AI analyst

See which prediction-market events move ABBV, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to ABBV from your Railway `news_articles` table.

3 High-Yield Dividend Stocks to Buy Hand Over Fist in June

Fool - Investing News • STOCK • 15/06/2026, 06:44:00

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

PRNewsWire • STOCK • 12/06/2026, 05:00:00

AbbVie: Growth-Pharma Profile At A Value-Pharma Price

Seeking Alpha • STOCK • 11/06/2026, 16:54:57

Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225

24/7 Wall Street • STOCK • 11/06/2026, 16:22:07

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ETF Trends • STOCK • 11/06/2026, 09:14:42

3 Dividend Stocks Built for Retirement to Buy in June

24/7 Wall Street • STOCK • 10/06/2026, 18:05:21

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

GlobeNewsWire • STOCK • 10/06/2026, 13:47:00

AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 21:12:11

Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike

Zacks Investment Research • STOCK • 09/06/2026, 13:01:19

Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?

Zacks Investment Research • STOCK • 08/06/2026, 15:21:11

AbbVie, UnitedHealth, Sabra Health Care And A Consumer Defensive Stock On CNBC's 'Final Trades'

Benzinga • STOCK • 08/06/2026, 09:38:51

Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?

The Motley Fool • STOCK • 08/06/2026, 03:45:00